How Mounjaro Works

Mounjaro MOA video ||| h6

Coming soon

Select Important Safety Information

Acute Gallbladder Disease ||| mounjaro-purple

In clinical trials, acute gallbladder disease was reported by 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.

Mounjaro works differently than a GLP-1 RA1

Tirzepatide is the first and only approved single molecule that activates GIP and GLP-1 receptors in the body.1

Mounjaro acts in the following ways1

1. ENHANCES

insulin secretion

2. IMPROVES

insulin sensitivity.

3. DECREASES

food intake.

Additional actions include delayed gastric emptying*and reduced glucagon levels.

Resulting in lower glucose concentration in both fasting and postprandial states.

*This effect diminishes over time.

GIP=glucose-dependent insulinotropic polypeptide; GLP-1=glucagon-like peptide-1; RA=receptor agonist; T2D=type 2 diabetes.

Reference:

  1. Mounjaro. Prescribing Information. Lilly USA, LLC.